At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 99 enrolled
Drug / intervention
BIBF 1120 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Open Label, Parallel Group Phase II Study Comparing the Efficacy and Tolerability of BIBF 1120 Versus Sunitinib in Previously Untreated Patients With Renal Cell Cancer
In Brief
A Phase 2 clinical trial evaluating BIBF 1120 and sunitinib for Carcinoma, Renal Cell. Completed, enrolled 99 participants across 15 sites in 5 countries.
Detailed Summary
Compare safety and efficacy of BIBF 1120 versus sunitinib in patients with advanced RCC and to investigate the effects of BIBF 1120 on the heart rate (HR) corrected QT interval (QTcF).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesHungary, Poland, Romania, Ukraine, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartDec 2009
Primary CompletionNov 2011
Study CompletionJun 2020
TodayJul 2026
First PostedDec 3, 2009
Enrollment StartDec 16, 2009
Primary CompletionNov 8, 2011
Study CompletionJun 19, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 16.6 years ago
Interventions
BIBF 1120drug
VEGF inhibitor
sunitinibdrug
VEGF inhibitor